Bone Drug Prevents Breast Cancer Return
Zometa May Lower Relapse Rate for Early-Stage Breast Cancer Patients
Zometa's Antitumor Effects continued...
Five years later, the risk of relapse was 36% lower in women taking either hormone therapy plus Zometa, compared with hormone therapy alone.
Overall, cancer came back in 6% of women who received Zometa vs. 9% who got the placebo.
There were no differences in the results between women taking tamoxifen and those taking Arimidex.
Zometa was well tolerated, and none of the women developed kidney damage or jaw bone death, two side effects that have been linked to bisphosphonate drugs.
The trial was funded in part by Novartis, which makes Zometa.
Julie Gralow, MD, chairwoman of ASCO's communications committee and a breast cancer specialist at the University of Washington, says that "the findings will change practice."
Based on these data, many breast cancer doctors will start offering the drug to their patients, she tells WebMD.
Eric Winer, MD, a breast cancer specialist at the Dana-Farber Cancer Institute in Boston, agrees that doctors have a responsibility to share the new findings with their patients.
"For some premenopausal women with estrogen-responsive tumors, this will be another option. But in my view, this is not for all women," he tells WebMD.
Winer notes that while Zometa has been shown to cut the chance of relapse, it has not yet been shown to actually extend lives. And "while not a terribly toxic drug, all drugs have toxicities," he says.
A trial testing Zometa in postmenopausal women recently ended, and those results will be out in a few months, Winer adds. Until those findings are known, the drug should not be given to postmenopausal women, he says.
Breast cancer will be diagnosed in more than 180,000 women in 2008, according to the American Cancer Society. About 20,000 to 25,000 of them will be hormone-fueled tumors in premenopausal women; for now, these are the women who are candidates for Zometa treatment, Winer says.
Avastin Shrinks Advanced Breast Tumors
Also at the meeting, researchers reported that for women with advanced breast cancer, a combination of Avastin and the chemotherapy drug Taxotere beats out Taxotere alone.
The researchers studied 736 women, all of whom received Taxotere. Tumors shrank in 63% of those who were also given a high dose of Avastin, 55% of those given a low dose of Avastin, and 44% given a placebo.
The study didn't have enough women to prove that the higher Avastin dose was better than the lower one; however, either dose was significantly better than placebo.
Avastin prevents tumors from growing new blood vessels, thereby choking them to death. It is approved to treat metastatic breast cancer as well as late-stage colorectal cancer and late-stage lung cancer.
Taxotere is a member of a class of chemotherapy drugs called taxanes that that help slow tumor growth by preventing cell division.
The trial was sponsored by Roche, which makes Avastin.